1253188-22-5 Usage
Description
(4-(benzyloxy)-2-(trifluoromethyl)phenyl)methanol, also known as tramiprosate, is a small molecule belonging to the class of glycosaminoglycans (GAG) analogs. It has demonstrated potential in the treatment of Alzheimer's disease by reducing the accumulation of beta-amyloid protein in the brain, which is associated with the development of this condition. Tramiprosate is believed to inhibit the formation and aggregation of beta-amyloid protein, offering a promising avenue for therapeutic intervention in Alzheimer's disease.
Uses
Used in Pharmaceutical Industry:
(4-(benzyloxy)-2-(trifluoromethyl)phenyl)methanol is used as a therapeutic agent for the treatment of Alzheimer's disease. Its application is based on its ability to reduce the accumulation of beta-amyloid protein in the brain, which is linked to the development and progression of this neurodegenerative condition. Clinical trials have shown potential cognitive benefits in patients with mild-to-moderate Alzheimer's disease, positioning tramiprosate as a candidate for the development of new treatments to address this devastating condition.
Check Digit Verification of cas no
The CAS Registry Mumber 1253188-22-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,3,1,8 and 8 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1253188-22:
(9*1)+(8*2)+(7*5)+(6*3)+(5*1)+(4*8)+(3*8)+(2*2)+(1*2)=145
145 % 10 = 5
So 1253188-22-5 is a valid CAS Registry Number.
1253188-22-5Relevant articles and documents
Optical Control of CRAC Channels Using Photoswitchable Azopyrazoles
Yang, Xingye,Ma, Guolin,Zheng, Sisi,Qin, Xiaojun,Li, Xiang,Du, Lupei,Wang, Youjun,Zhou, Yubin,Li, Minyong
, p. 9460 - 9470 (2020/06/27)
The Ca2+ release-activated Ca2+ (CRAC) channels control many Ca2+-modulated physiological processes in mammals. Hyperactivating CRAC channels are known to cause several human diseases, including Stormorken syndrome. Here, we show the design of azopyrazole-derived photoswitchable CRAC channel inhibitors (designated piCRACs), which enable optical inhibition of store-operated Ca2+ influx and downstream signaling. Moreover, piCRAC-1 has been applied in vivo to alleviate thrombocytopenia and hemorrhage in a zebrafish model of Stormorken syndrome in a light-dependent manner.
